Market Overview:
The global gastritis therapeutics market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of gastritis, rising awareness about available treatment options, and growing demand for novel therapies. By type, the acid-blocking medicines segment is expected to account for the largest share of the global gastritis therapeutics market in 2018. This segment is projected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. By application, hospitals are expected to account for the largest share of the global gastritis therapeutics market in 2018.
Product Definition:
Gastritis Therapeutics is the branch of medicine that deals with the treatment of gastritis. It is important because gastritis can lead to more serious diseases, such as stomach cancer.
Acid-Blocking Medicines:
Acid-blocking medicines are used to reduce stomach acid production. The normal pH of the stomach is 2.8-3.2, an ideal range for protein digestion and absorption; however, when the pH value rises above 3.5, it becomes more difficult for proteins to be absorbed into the blood stream resulting in gastric ulcer development (stomach cancer).
Antibiotics:
Antibiotics Market By Product (Penicillin, Cephalosporin, Macrolides & Monobactams) And Segment Forecasts To 2020 -> Growing prevalence of bacterial infections is expected to drive the global antibiotics market. Increasing incidences of hospital-acquired infections and rising awareness levels amongst patients are some key drivers for this market.
Application Insights:
Based on application, the global gastritis therapeutics market is segmented into hospitals, clinics and other medical facilities. Hospitals held the largest share in 2017 owing to factors such as high patient admissions due to acute diseases. In addition, hospitals are considered centers of excellence in gastroenterology and thus have a high preference for treatment of chronic conditions related to stomach and intestines.
The clinics and other medical facilities segment is expected to witness lucrative growth over the forecast period due to increasing awareness about digestive disorders among general population coupled with rising incidences of chronic conditions such as acid reflux disease (ARCD) & peptic ulcers that require longterm medication management. For instance, according Gastroenterology Associates Of Pensacola - Gulf Coast Clinic Inc., patients suffering from heartburn or indigestion are encouraged by their doctors to undergo lifestyle modifications along with medication therapy for better results.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing prevalence of gastritis and other associated diseases, such as diabetes and obesity. In addition, rising adoption of westernized lifestyle is also one of the factors responsible for maintaining dominance.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to improving economic conditions in emerging countries like India and China. Furthermore, growing medical tourism industry will also boost demand for treatment options in this region eventually driving growth through 2030 forecasted date). Other factors contributing toward regional growth include increasing awareness about early diagnosis & management techniques coupled with rising healthcare expenditure by governments & private sectors across various countries including India, China, Japan among others are expected to drive regional expansion over next seven years as a result’s quick relief from symptoms' helps ease patient's suffering thereby boosting sales through 2030 forecasted date)'.
Growth Factors:
- Increasing incidence of gastritis across the globe
- Rising awareness about the available treatment options for gastritis
- Growing demand for better and more effective therapies for gastritis
- Technological advancements in the field of Gastritis therapeutics market 5. Availability of government funding and support for research and development activities in Gastritis therapeutics market
Scope Of The Report
Report Attributes
Report Details
Report Title
Gastritis Therapeutics Market Research Report
By Type
Acid-Blocking Medicines, Antibiotics, Antacids, Histamine Blockers, Others
By Application
Hospitals, Clinics, Others
By Companies
Pfizer, AstraZeneca, Novartis, Cipla, Abbott Laboratories, Microbiotix, Reddy's Laboratories, Lupin Ltd, Perrigo Pharmaceutical, Sun Pharmaceutical Industries
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
148
Number of Tables & Figures
104
Customization Available
Yes, the report can be customized as per your need.
Global Gastritis Therapeutics Market Report Segments:
The global Gastritis Therapeutics market is segmented on the basis of:
Types
Acid-Blocking Medicines, Antibiotics, Antacids, Histamine Blockers, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- AstraZeneca
- Novartis
- Cipla
- Abbott Laboratories
- Microbiotix
- Reddy's Laboratories
- Lupin Ltd
- Perrigo Pharmaceutical
- Sun Pharmaceutical Industries
Highlights of The Gastritis Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Acid-Blocking Medicines
- Antibiotics
- Antacids
- Histamine Blockers
- Others
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Gastritis Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Gastritis Therapeutics is a biotechnology company focused on the development of novel therapeutics for gastritis. The company's lead product candidate, GSK-3308, is an investigational drug that is in Phase III clinical trials for the treatment of gastritis.
Some of the key players operating in the gastritis therapeutics market are Pfizer, AstraZeneca, Novartis, Cipla, Abbott Laboratories, Microbiotix, Reddy's Laboratories, Lupin Ltd, Perrigo Pharmaceutical, Sun Pharmaceutical Industries.
The gastritis therapeutics market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Gastritis Therapeutics Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Gastritis Therapeutics Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Gastritis Therapeutics Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Gastritis Therapeutics Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Gastritis Therapeutics Market Size & Forecast, 2020-2028 4.5.1 Gastritis Therapeutics Market Size and Y-o-Y Growth 4.5.2 Gastritis Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Acid-Blocking Medicines
5.2.2 Antibiotics
5.2.3 Antacids
5.2.4 Histamine Blockers
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Gastritis Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Gastritis Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Acid-Blocking Medicines
9.6.2 Antibiotics
9.6.3 Antacids
9.6.4 Histamine Blockers
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Acid-Blocking Medicines
10.6.2 Antibiotics
10.6.3 Antacids
10.6.4 Histamine Blockers
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Acid-Blocking Medicines
11.6.2 Antibiotics
11.6.3 Antacids
11.6.4 Histamine Blockers
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Acid-Blocking Medicines
12.6.2 Antibiotics
12.6.3 Antacids
12.6.4 Histamine Blockers
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Acid-Blocking Medicines
13.6.2 Antibiotics
13.6.3 Antacids
13.6.4 Histamine Blockers
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Gastritis Therapeutics Market: Competitive Dashboard
14.2 Global Gastritis Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 AstraZeneca
14.3.3 Novartis
14.3.4 Cipla
14.3.5 Abbott Laboratories
14.3.6 Microbiotix
14.3.7 Reddy's Laboratories
14.3.8 Lupin Ltd
14.3.9 Perrigo Pharmaceutical
14.3.10 Sun Pharmaceutical Industries